Hospital acquired infections
Patients admitted to or visiting hospitals can develop multiple infections, which are known as hospital-acquired infections (HAIs), or, simply, hospital infections. These conditions generally spread within nursing homes, dialysis centres, rehabilitation centres, outpatient surgery centres, and hospitals. Various bacterial, fungal, and viral pathogens can cause hospital infections. Intensive care units are also a common source of HAIs, which can be treated using antimicrobial drugs. Some therapeutic drugs available for these diseases are CAZ AVI, Surotomycin, MK-3415A, and Ceftolozane.
The growing susceptibility of the neonatal population to HAIs and the booming supply of drugs for these conditions is likely to lead to massive growth in the hospital infection therapeutics market in the coming years. Moreover, the lack of skilled nursing staff in healthcare settings, especially in emerging economies, is a key factor making therapeutic drugs more important. In many countries, these factors will offer pharmaceutical companies the opportunity to increase their production capacity in the coming years.
The number of hospitals is also rising worldwide, primarily due to government efforts to make healthcare more accessible. The World Bank reports the number of hospital beds per 1,000 people around the world increased to 2.894 in 2017 from 2.462 in 2005. A higher number of hospital beds means a larger number of hospital patients, which translates into a higher incidence of various HAIs. Ultimately, this will increase the demand for therapeutic drugs in the coming years.
North America has emerged as the hospital infection therapeutics market leader. The reason is the higher ratio of hospitals to the population of the region compared to other parts of the world. The surging population of ageing people in the continent and the increasing number of multi-drug-resistant microbial pathogens are also significant reasons leading to the rising demand for therapeutic drugs. APAC is also witnessing a rising demand for therapeutic drugs, especially in China and India, due to the growing prevalence of HAIs.
[edit] Related articles on Designing Buildings
Featured articles and news
About the 5 Percent Club and its members
The 5% Club; a dynamic movement of employers committed to building and developing the workforce.
New Homes in New Ways at the Building Centre
Accelerating the supply of new homes with MMC.
Quality Planning for Micro and Small to Medium Sized Enterprises
A CIOB Academy Technical Information sheet.
A briefing on fall protection systems for designers
A legal requirement and an ethical must.
CIOB Ireland launches manifesto for 2024 General Election
A vision for a sustainable, high-quality built environment that benefits all members of society.
Local leaders gain new powers to support local high streets
High Street Rental Auctions to be introduced from December.
Infrastructure sector posts second gain for October
With a boost for housebuilder and commercial developer contract awards.
Sustainable construction design teams survey
Shaping the Future of Sustainable Design: Your Voice Matters.
COP29; impacts of construction and updates
Amid criticism, open letters and calls for reform.
The properties of conservation rooflights
Things to consider when choosing the right product.
Adapting to meet changing needs.
London Build: A festival of construction
Co-located with the London Build Fire & Security Expo.
Tasked with locating groups of 10,000 homes with opportunity.
Delivering radical reform in the UK energy market
What are the benefits, barriers and underlying principles.
Information Management Initiative IMI
Building sector-transforming capabilities in emerging technologies.
Recent study of UK households reveals chilling home truths
Poor insulation, EPC knowledge and lack of understanding as to what retrofit might offer.
Comments
[edit] To make a comment about this article, or to suggest changes, click 'Add a comment' above. Separate your comments from any existing comments by inserting a horizontal line.